The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

Cash runway is robust for now, taking CARGO Therapeutics into 2028 after a planned workforce reduction. Read why I am neutral ...